T CELLS EXPRESSING CHEMOKINE RECEPTORS FOR TREATING CANCER
The present disclosure relates to methods and products for preventing and/or treating cancer, and in particular to methods, cells and products for preventing and/or treating cancer using adoptive immunotherapies. In certain embodiments, the present disclosure provides a method of treating a subject suffering from, or susceptible to, a cancer associated with chemokine expressing cells, the method comprising exposing the subject to T cells expressing a receptor to the chemokine and thereby treating the subject.
1 - 25 . (canceled)
26 . A method of treating a central nervous system (CNS) disorder or disease in a subject, the method comprising administering, to the subject, lymphocytes engineered to express a chemokine receptor, wherein the chemokine receptor is CCR2 and/or CCR6.
27 . The method according to claim 26 , wherein the CNS disorder or disease is cancer.
28 . The method according to claim 27 , wherein the cancer is glioma, neuroblastoma, or a CNS-localised secondary tumour.
29 . The method according to claim 28 , wherein the glioma is selected from the group consisting of: astrocytoma, ependymomas, oligodendrogliomas, brainstem glioma, optic nerve glioma or a mixed glioma.
30 . The method according to claim 26 , wherein the CNS disorder or disease is an autoimmune disease.
31 . The method according to claim 30 , wherein the CNS autoimmune disease is autoimmune encephalomyelitis.
32 . The method according to claim 26 , wherein the lymphocyte expresses both CCR2 and CCR6.
33 . The method according to claim 26 , wherein the lymphocyte expresses a chimeric antigen receptor.
34 . The method according to claim 26 , wherein the lymphocyte is a T cell.
35 . The method according to claim 34 , wherein the T cell is a CD4+ T cell.
36 . The method according to claim 34 , wherein the T cell is a CD8+ T cell.
37 . The method according to claim 34 , wherein the T cell is an NKT cell.
38 . The method according to claim 34 , wherein the T cell is a gamma delta (γδ) T cell.
39 . The method according to claim 38 , wherein the gamma delta T cell produces interleukin 17.
40 . The method according to claim 26 , wherein the lymphocyte is a NK cell.
41 . The method according to claim 26 , wherein the lymphocyte is engineered to further comprise one or more chemokine receptor selected from the group consisting of: CXCR3, CCR9, CCR10, CXCR4, CXCR6, CXCR5, XCR1 and CCR5.
42 . The method according to claim 27 , further comprising the step of determining the expression of a chemokine in the cancer prior to administration of the lymphocytes to the subject.
43 . The method of claim 26 , wherein the lymphocyte is engineered to overexpress the chemokine receptor.